130 likes | 446 Views
Bezafibrate Infarction Prevention Trial (BIP). Results Presented at the European Society of Cardiology Meeting Vienna, Austria 1998. BIP - Study Design. 3,122 men and women between 45 and 75 with documented CAD. 400 mg bezafibrate vs. placebo. Lipid parameters: LDL < 180 mg/dL
E N D
Bezafibrate Infarction Prevention Trial (BIP) Results Presented at the European Society of Cardiology Meeting Vienna, Austria 1998
BIP - Study Design • 3,122 men and women between 45 and 75 with documented CAD. • 400 mg bezafibrate vs. placebo. • Lipid parameters: • LDL < 180 mg/dL • TG < 300 mg/dL • HDL < 45 mg/dL • TC 180-250 mg/dL • Primary endpoint: • CHD death and non-fatal MI
BIP - Baseline Characteristics Characteristic Age, yr 60 Women 9% Current Smokers 11% Diabetics 10% Hypertension 32% Prior MI 78% ASA use 70% Beta Blocker use 38% ACEI use 12%
BIP - Baseline Lipids • TC 212 mg/dL • LDL 148 mg/dL • HDL 35 mg/dL • TG 149 mg/dL
BIP - Primary Endpoint 9% relative risk reduction p=0.27
BIP - Conclusion • The primary endpoint was not significantly effected by bezafibrate therapy. • In a subset of patients with baseline TG > 200 mg/dL (n=459), there was a 40% reduction in the primary endpoint (p=0.03)
Why Was VA-HIT Positive and BIP Negative? • BIP • bezafibrate 400 mg/day • VA-HIT • gemfibrozil 1200 mg/day • The VA-HIT population was: • Older • More obese • More hypertensive • More diabetics • More smokers • Had lower baseline LDL/HDL
VA-HIT vs. BIPBaseline Characteristics Characteristic BIP (n=3,122) VA-HIT (n-2,531) LDL, mg/dL 148 111 TG, mg/dL 149 161 HDL, mg/dL 35 32 TC, mg/dL 212 175 Mean age, y 60 64 (70% > 60) Hypertension, % 32 57 Smokers, % 11 21 Diabetes, % 10 25 BMI 27 29